ADvantage Therapeutics

Quick facts

Phase 2 pipeline

• AD04 · Diabetes
  AD04 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ADvantage Therapeutics portfolio CI brief
• ADvantage Therapeutics pipeline updates RSS

Related

• Sector hub: All tracked pharma companies